Overview

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Status:
NOT_YET_RECRUITING

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized, multi-cohort, multi-center, phase Ib/II study to evaluate the safety and efficacy of Adebrelimab plus Irinotecan Liposome (II) with or without Famitinib in patients with extensive-stage small cell lung cancer (ES-SCLC) pre-treated with immune checkpoint inhibitor(s).

Phase:

PHASE1

Details

Lead Sponsor:

Baohui Han

Treatments:

famitinib
irinotecan sucrosofate